Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Other Operating Expenses (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Other Operating Expenses for 3 consecutive years, with -$241976.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 126.78% to -$241976.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, up 171.45% year-over-year, with the annual reading at -$125624.0 for FY2025, 102.35% down from the prior year.
  • Other Operating Expenses hit -$241976.0 in Q4 2025 for Mangoceuticals, down from $7.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $7.3 million in Q3 2025 to a low of -$241976.0 in Q4 2025.
  • Historically, Other Operating Expenses has averaged $2.3 million across 3 years, with a median of $1.8 million in 2023.
  • Biggest YoY gain for Other Operating Expenses was 453.0% in 2025; the steepest drop was 126.78% in 2025.
  • Year by year, Other Operating Expenses stood at $1.9 million in 2023, then crashed by 52.13% to $903710.0 in 2024, then plummeted by 126.78% to -$241976.0 in 2025.
  • Business Quant data shows Other Operating Expenses for MGRX at -$241976.0 in Q4 2025, $7.3 million in Q3 2025, and $4.1 million in Q2 2025.